Evolution of Therapeutic Antibodies, Influenza Virus Biology, Influenza, and Influenza Immunotherapy

BioMed Research International
Urai Chaisri, Wanpen Chaicumpa

Abstract

This narrative review article summarizes past and current technologies for generating antibodies for passive immunization/immunotherapy. Contemporary DNA and protein technologies have facilitated the development of engineered therapeutic monoclonal antibodies in a variety of formats according to the required effector functions. Chimeric, humanized, and human monoclonal antibodies to antigenic/epitopic myriads with less immunogenicity than animal-derived antibodies in human recipients can be produced in vitro. Immunotherapy with ready-to-use antibodies has gained wide acceptance as a powerful treatment against both infectious and noninfectious diseases. Influenza, a highly contagious disease, precipitates annual epidemics and occasional pandemics, resulting in high health and economic burden worldwide. Currently available drugs are becoming less and less effective against this rapidly mutating virus. Alternative treatment strategies are needed, particularly for individuals at high risk for severe morbidity. In a setting where vaccines are not yet protective or available, human antibodies that are broadly effective against various influenza subtypes could be highly efficacious in lowering morbidity and mortality and controlling u...Continue Reading

References

Dec 1, 1975·Virology·H D KlenkJ Blödorn
May 15, 1992·Cell·A Helenius
Oct 1, 1986·The Journal of Cell Biology·C S CopelandA Helenius
Sep 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·M BrüggemannM S Neuberger
Dec 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·C QueenT A Waldmann
Dec 1, 1989·The Journal of Experimental Medicine·M BrüggemannM S Neuberger
Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A F LoBuglioM B Khazaeli
Mar 24, 1988·Nature·L RiechmannG Winter
Jun 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·C A BorrebaeckS A Möller
Sep 1, 1988·Journal of Clinical Microbiology·W ChaicumpaM Chongsa-Nguan
Nov 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S L MorrisonV T Oi
Sep 2, 1982·The New England Journal of Medicine·R DolinJ Webber-Jones
Jan 1, 1995·International Reviews of Immunology·N Lonberg, D Huszar
Mar 1, 1995·Journal of Virology·Z YeR R Wagner
Jan 1, 1994·Annual Review of Immunology·G WinterH R Hoogenboom
Feb 1, 1994·Proceedings of the National Academy of Sciences of the United States of America·M A RoguskaB C Guild
Jan 1, 1993·Intervirology·R G WebsterY Kawaoka
May 1, 1993·Proteins·T T WuE A Kabat
Jun 3, 1993·Nature·C Hamers-CastermanR Hamers
May 1, 1996·Journal of Virology·G WhittakerA Helenius
Jul 1, 1996·Emerging Infectious Diseases·A Casadevall
May 13, 1997·Proceedings of the National Academy of Sciences of the United States of America·J Hanes, A Plückthun
Jun 1, 1997·Nature Biotechnology·E T Boder, K D Wittrup
Jul 15, 1997·Nucleic Acids Research·M C MorrisG Divita

❮ Previous
Next ❯

Citations

Aug 10, 2021·Biological Trace Element Research·Fatemeh SadeghsoltaniMostafa Vaghari-Tabari

❮ Previous
Next ❯

Methods Mentioned

BETA
transgenic
PCR
antibody display
phage display

Software Mentioned

VBASE

Related Concepts

Related Feeds

Brucellosis

Brucellosis is a bacterial infection caused by members of the genus brucella and remains one of the world's major zoonotic diseases. Discover the latest research on Brucellosis here.

Brucellosis (ASM)

Brucellosis is a bacterial infection caused by members of the genus brucella and remains one of the world's major zoonotic diseases. Discover the latest research on Brucellosis here.

© 2022 Meta ULC. All rights reserved